Wakamoto Pharmaceutical Co.,Ltd.
Stock Price Chart
2026/09/29 18:54 UpdatedPrice Trend
2026/09/29 18:54 UpdatedPrice & Trading Details
2026/09/29 18:54 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/09/01Dividend History 1Years Growth
Updated 2026/09/27| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥4 | +16.7% |
| 2025 | ¥3 | 0.0% |
| 2024 | ¥3 | 0.0% |
| 2023 | ¥3 | 0.0% |
| 2018 | ¥3 | - |
Financial Performance
2026/09/27 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥8,660M | ¥7,738M | ¥7,789M | ¥9,907M |
| Gross Profit | ¥4,108M | ¥3,600M | ¥3,622M | ¥4,730M |
| Operating Income | ¥141M | -¥196M | -¥458M | ¥256M |
| Pretax Income | ¥212M | ¥159M | ¥8M | ¥258M |
| Net Income | ¥138M | ¥109M | ¥64M | ¥227M |
| EPS | ¥3.98 | ¥3.13 | ¥1.85 | ¥6.54 |
| Operating Margin | 1.63% | -2.53% | -5.88% | 2.58% |
| Balance Sheet | ||||
| Total Assets | ¥15,712M | ¥15,421M | ¥15,003M | ¥16,500M |
| Total Equity | ¥11,907M | ¥12,026M | ¥11,610M | ¥12,009M |
| Total Liabilities | ¥3,805M | ¥3,395M | ¥3,392M | ¥4,491M |
| Cash | ¥3,879M | ¥3,665M | ¥2,955M | ¥2,006M |
| Interest-bearing Debt | ¥138M | ¥131M | ¥129M | ¥400M |
| Equity Ratio | 75.78% | 77.98% | 77.39% | 72.78% |
| D/E Ratio | 0.01 | 0.01 | 0.01 | 0.03 |
| Cash Flow | ||||
| Operating CF | ¥632M | -¥107M | -¥592M | -¥487M |
| Investing CF | ¥17M | -¥2M | -¥13M | -¥658M |
| Financing CF | -¥2M | -¥105M | -¥104M | ¥196M |
| Free CF | ¥421M | -¥702M | -¥1,089M | -¥1,141M |
| Efficiency | ||||
| ROE | 1.16% | 0.91% | 0.56% | 1.89% |
| ROA | 0.88% | 0.71% | 0.43% | 1.38% |
Latest IR Information
-
Notice Regarding Change of Major Shareholder, the Principal Shareholder
Notification of change in major shareholder. New principal shareholder is Asset Value Investors Limited (UK), with voting rights increased to 11.70%. Lohaco? Wait: note: original says ロート製薬; translated as Rohto Pharmaceutical Co., Ltd. remains as second place. No further outlook...
Read more -
First Quarter Financial Summary for the Fiscal Year Ending March 2027 (Japanese GAAP) (Consolidated)
Net sales were 2.425 billion yen (up 11.9% YoY), operating loss was 136 million yen, and quarterly net income was 6 million yen. Due to drug price revision, gross profit declined. Conversely, gains on sales of marketable securities were recorded,...
Read more
Latest News (5 items)
Company Information
About
Wakamoto Pharmaceutical Co.,Ltd. is engaged in the manufacture and sale of pharmaceuticals, medical devices, and health food in Japan. It operates through four segments: Pharmaceutical Business, Healthcare Business, Global Business, and Real Estate Leasing Business. The company offers Strong and Granule Wakamoto, gastrointestinal drugs for digestion, intestinal regulation, and nutritional supplementation, as well as Wakamoto Intestinal Remedy drug. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co.,Ltd. in July 1943. Wakamoto Pharmaceutical Co.,Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.
